Roche has announced a $7.1 billion deal to acquire Roivant group company Telavant and its RVT-301 drug candidate for inflammatory bowel disease (IBD), confirming rumours t
Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco
The latest start-up to emerge from the Roivant stable is named Priovant Therapeutics, and has been formed to develop a JAK1/TYK2 inhibitor originated by Pfizer as a treatment for autoimmune
Just two years after buying rights to psoriasis candidate tapinarof from GlaxoSmithKline, Swiss biotech Dermavant says it could be a few months away from filing for approval of
Roche is to begin a phase 3 trial of its Actemra/RoActemra as a treatment for patients hospitalised with severe COVID-19 pneumonia, following independent research in China suggesting it may
South Korea’s Hyundai Bioscience is preparing to start clinical trials of what it hopes could become the first antiviral treatment for dengue fever, a mosquito-borne viral
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.